Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

How reliable and useful are angiogenesis blood mediators for prostate cancer diagnosis?

Balacescu O, Crisan N, Balacescu L, Visan S, Tudoran O, Fetica B, Bungardean C, Marian C, Petrut B.

J BUON. 2019 May-Jun;24(3):1194-1203.

2.

New alginate-pullulan-bioactive glass composites with copper oxide for bone tissue regeneration trials.

Popescu RA, Magyari K, Taulescu M, Vulpoi A, Berce C, Bogdan S, Lelescu C, Dreancă A, Tudoran O, Papuc I, Baia L.

J Tissue Eng Regen Med. 2018 Oct;12(10):2112-2121. doi: 10.1002/term.2746. Epub 2018 Aug 16.

PMID:
30070023
3.

Urinary microRNAs for prostate cancer diagnosis, prognosis, and treatment response: are we there yet?

Balacescu O, Petrut B, Tudoran O, Feflea D, Balacescu L, Anghel A, Sirbu IO, Seclaman E, Marian C.

Wiley Interdiscip Rev RNA. 2017 Nov;8(6). doi: 10.1002/wrna.1438. Epub 2017 Aug 16. Review.

PMID:
28815924
4.

The Many Faces of Long Noncoding RNAs in Cancer.

Wu X, Tudoran OM, Calin GA, Ivan M.

Antioxid Redox Signal. 2018 Sep 20;29(9):922-935. doi: 10.1089/ars.2017.7293. Epub 2017 Oct 20. Review.

5.

The Role of Bioactive Dietary Components in Modulating miRNA Expression in Colorectal Cancer.

Gavrilas LI, Ionescu C, Tudoran O, Lisencu C, Balacescu O, Miere D.

Nutrients. 2016 Sep 26;8(10). pii: E590. Review.

6.

Novel Strategies for the Improvement of Stem Cells' Transplantation in Degenerative Retinal Diseases.

Nicoară SD, Șușman S, Tudoran O, Bărbos O, Cherecheș G, Aștilean S, Potara M, Sorițău O.

Stem Cells Int. 2016;2016:1236721. doi: 10.1155/2016/1236721. Epub 2016 May 18. Review.

7.

Breast cancer stem-like cells: clinical implications and therapeutic strategies.

Tudoran OM, Balacescu O, Berindan-Neagoe I.

Clujul Med. 2016;89(2):193-8. doi: 10.15386/cjmed-559. Epub 2016 Apr 15. Review.

8.

Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients.

Balacescu O, Balacescu L, Virtic O, Visan S, Gherman C, Drigla F, Pop L, Bolba-Morar G, Lisencu C, Fetica B, Tudoran O, Berindan-Neagoe I.

Mediators Inflamm. 2016;2016:3239167. doi: 10.1155/2016/3239167. Epub 2016 Jan 13.

9.

Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response.

Tudoran O, Virtic O, Balacescu L, Lisencu C, Fetica B, Gherman C, Balacescu O, Berindan-Neagoe I.

Onco Targets Ther. 2015 Nov 18;8:3415-23. doi: 10.2147/OTT.S91720. eCollection 2015.

10.

Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.

Tudoran O, Soritau O, Balacescu L, Visan S, Barbos O, Cojocneanu-Petric R, Balacescu O, Berindan-Neagoe I.

Mol Cell Biochem. 2015 Nov;409(1-2):163-76. doi: 10.1007/s11010-015-2522-z. Epub 2015 Jul 18.

PMID:
26187676
11.

PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation.

Tudoran OM, Soritau O, Balacescu L, Pop L, Meurice G, Visan S, Lindberg S, Eniu A, Langel U, Balacescu O, Berindan-Neagoe I.

J Cell Mol Med. 2015 Feb;19(2):371-82. doi: 10.1111/jcmm.12449. Epub 2014 Oct 14.

12.

Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients.

Tudoran O, Virtic O, Balacescu L, Pop L, Dragla F, Eniu A, Fetica B, Balacescu O, Berindan-Neagoe I.

PLoS One. 2014 Jul 28;9(7):e102764. doi: 10.1371/journal.pone.0102764. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e110962.

13.

The value of new high-throughput technologies for diagnosis and prognosis in solid tumors.

Pinto R, De Summa S, Petriella D, Tudoran O, Danza K, Tommasi S.

Cancer Biomark. 2014;14(2-3):103-17. doi: 10.3233/CBM-130328. Review.

PMID:
24878811
14.

Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure.

Balacescu O, Balacescu L, Tudoran O, Todor N, Rus M, Buiga R, Susman S, Fetica B, Pop L, Maja L, Visan S, Ordeanu C, Berindan-Neagoe I, Nagy V.

BMC Cancer. 2014 Apr 8;14:246. doi: 10.1186/1471-2407-14-246.

15.

Sensitive and rapid detection of Chlamydia trachomatis by recombinase polymerase amplification directly from urine samples.

Krõlov K, Frolova J, Tudoran O, Suhorutsenko J, Lehto T, Sibul H, Mäger I, Laanpere M, Tulp I, Langel Ü.

J Mol Diagn. 2014 Jan;16(1):127-35. doi: 10.1016/j.jmoldx.2013.08.003.

PMID:
24331366
16.

CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations.

Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, Zhang X, de Weerd V, Shimizu M, Ling H, Buiga R, Pop V, Irimie A, Fodde R, Bedrosian I, Martens JW, Foekens JA, Berindan-Neagoe I, Calin GA.

Oncotarget. 2013 Oct;4(10):1748-62.

17.

PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors.

Lindberg S, Muñoz-Alarcón A, Helmfors H, Mosqueira D, Gyllborg D, Tudoran O, Langel U.

Int J Pharm. 2013 Jan 30;441(1-2):242-7. doi: 10.1016/j.ijpharm.2012.11.037. Epub 2012 Nov 28.

PMID:
23200958
18.

Early apoptosis signals induced by a low dose of epigallocatechin 3-gallate interfere with apoptotic and cell death pathways.

Berindan-Neagoe I, Braicu C, Tudoran O, Balacescu O, Irimie A.

J Nanosci Nanotechnol. 2012 Mar;12(3):2113-9.

PMID:
22755028
19.

Identifying molecular features for prostate cancer with Gleason 7 based on microarray gene expression profiles.

Bălăcescu L, Bălăcescu O, Crişan N, Fetica B, Petruţ B, Bungărdean C, Rus M, Tudoran O, Meurice G, Irimie A, Dragoş N, Berindan-Neagoe I.

Rom J Morphol Embryol. 2011;52(4):1195-202.

20.

Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides.

Ezzat K, Helmfors H, Tudoran O, Juks C, Lindberg S, Padari K, El-Andaloussi S, Pooga M, Langel U.

FASEB J. 2012 Mar;26(3):1172-80. doi: 10.1096/fj.11-191536. Epub 2011 Dec 1.

PMID:
22138034

Supplemental Content

Loading ...
Support Center